A HUMAN IL-1 INHIBITOR FOR THE TREATMENT OF SEPTIC SHOCK

Award Information
Agency:
Department of Defense
Amount:
$49,326.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
Navy
Award Year:
1988
Phase:
Phase I
Agency Tracking Number:
9168
Solicitation Topic Code:
N/A
Small Business Information
Synergen Inc
1885 - 33rd St, Boulder, CO, 80301
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 DR CHARLES H HANNUM
 (303) 938-6200
Business Contact
Phone: () -
Research Institution
N/A
Abstract
WE PROPOSE TO PURIFY AN IL-1 INHIBITOR FROM THE SUPERNATANT OF MONOCYTES CULTURED ON PLATES COATED WITH IGG. THIS INHIBITORY ACTIVITY HAS BEEN SHOWN TO BE ABOUT 22 KILODALTONS IN MOLECULAR WEIGHT AND TO INHIBIT IL-1 IN SEVERAL ASSAYS, NAMELY IL-1 MEDIATED THYMOCYTE PROLIFERATION, COLLAGENASE RELEASE BY ARTICULAR CHONDROCYTES, AND PGE(2) RELEASE BY BOTH SYNOVIAL AND DERMAL FIBROBLASTS. WE WILL PRODUCE LARGE QUANTITIES OF THE INHIBITOR-CONTAINING SUPERNATANT AND PURIFY THE PROTEIN BY CONVENTIONAL CHROMATOGRAPHIC TECHNIQUES. INITIALLY WE WILL USE THE THYMOCYTE-PROFILERATION ASSAY TO MONITOR PURIFICATION BUT WILL IMMEDIATELY BEING DEVELOPING A FASTER PGE(2)-RELEASE ASSAY TO SPEED UP PURIFICATION. WE ALSO WILL BEGIN DEVELOPING MONOCLONAL ANTIBODIES TO THIS MOLECULE. OUR PHASE-I GOALS ARE TO DEVELOP A RAPID ASSAY FOR THIS INHIBITOR AND TO ATTAIN A 400-FOLD PURIFICATION.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government